Home > Healthcare > Drug Device Combination > Therapeutic Systems > Cervical Dysplasia Market
Cervical Dysplasia Market size was valued at USD 675.5 million in 2023 and is estimated to grow at 7.1% CAGR from 2024 to 2032, due to the increasing prevalence of human papillomavirus (HPV) infections, which are closely linked to the development of cervical dysplasia.
For instance, according to the International Agency for Research on Cancer, the global prevalence of HPV infection in women with normal cytology is around 11-12%, with the highest rates in sub-Saharan Africa (24%), Eastern Europe (21%), and Latin America (16%). Thus, as more women are diagnosed with cervical dysplasia resulting from HPV, there is a growing demand for effective screening, diagnostic, and treatment options. Moreover, advancements in diagnostic technologies and the development of effective vaccines against high-risk HPV strains further boost the market growth.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Cervical Dysplasia Market Size in 2023: | USD 675.5 Million |
Forecast Period: | 2024 - 2032 |
Forecast Period 2024 - 2032 CAGR: | 7.1% |
2032 Value Projection: | USD 1.2 Billion |
Historical Data for: | 2021 - 2023 |
No. of Pages: | 160 |
Tables, Charts & Figures: | 292 |
Segments covered: | Type, Diagnosis and Treatment, End-user, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Cervical dysplasia is a medical condition characterized by the presence of abnormal cells on the surface of the cervix. These changes are not cancerous but can be considered precancerous, meaning they have the potential to develop into cervical cancer if left untreated. Cervical dysplasia is often detected through routine screening methods such as Pap smears or HPV DNA tests. It is commonly caused by persistent infection with high-risk types of HPV. Treatment options vary depending on the severity of the dysplasia and may include surgical procedures, and non-surgical procedures.